Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Apelin-12 peptide icon, one bubble per amino acidApelin-1212 residuesRPRLSHKGPMPFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Apelin-12

5 min half-life·Injection·4w on / 2w off

Also known as: Apelin(25-36), APLN(25-36), preproapelin(65-77)

A single IV dose dropped mean arterial pressure by 26 mmHg in normotensive rats. That number outperformed apelin-13 by more than double and apelin-36 by five times (Tatemoto et al.)[1]. Apelin-12 (RPRLSHKGPMPF, CAS 229961-08-4) is the shortest biologically active fragment of the 77-amino-acid preproapelin precursor. It binds the APJ receptor and triggers NO-dependent vasodilation through the PI3K/Akt/eNOS cascade. The limitation is hard to ignore: a plasma half-life of roughly five minutes. No human has ever been dosed with native apelin-12 in a clinical trial. Cardiovascular researchers study it for RAAS counter-regulation and cardioprotection in animal models.

What Is Apelin-12?

Twenty-six millimeters of mercury. That was the mean arterial pressure drop when Tatemoto's group injected 10 nmol/kg of apelin-12 intravenously into normotensive rats [1]. Apelin-13 managed 11 mmHg. Apelin-36 barely registered at 5 mmHg.

Apelin-12 (sequence RPRLSHKGPMPF, CAS 229961-08-4, MW 1422.7 Da) is the shortest active fragment cleaved from the C-terminal end of preproapelin. It binds APJ (APLNR), an orphan GPCR identified in 1993 and deorphanized in 1998 when apelin was isolated from bovine stomach tissue. The vasodilatory mechanism runs through PI3K/Akt/eNOS phosphorylation on endothelial cells; NOS inhibitors completely abolished the blood pressure response, confirming the pathway is obligately NO-dependent.

Nobody is self-administering this peptide. Zero Reddit threads exist across r/peptides, r/nootropics, and r/longevity. No grey-market product exists. It is sold only as a lab reagent for research, at $42 to $110 per milligram. The five-minute plasma half-life makes subcutaneous bioavailability a genuine open question.

Where apelin-12 matters is cardiovascular research. A 2026 systematic review pooling 26 preclinical studies confirmed cardioprotective effects across ischemia-reperfusion models (Khatami et al.)[2]. Apelin-knockout mice developed markedly worse cardiac fibrosis under angiotensin II challenge (Sato et al. 2019)[3]. Amgen's small-molecule APJ agonist AMG 986 reached Phase 1b in heart failure patients [4] but produced no clinically meaningful benefit. Early-stage research with genuine preclinical promise, but years from any human application.

How Apelin-12 Works

Apelin-12 locks onto APJ (APLNR), a class A GPCR expressed on vascular endothelial cells, cardiomyocytes, and smooth muscle. The receptor couples through Gi/o and Gq alpha subunits, firing multiple downstream signaling cascades depending on the tissue.

The vascular pathway is best characterized. APJ activation triggers PI3K, which phosphorylates Akt, which phosphorylates eNOS at Ser1177. Nitric oxide floods the local environment. NO diffuses into adjacent smooth muscle cells, activates soluble guanylyl cyclase, raises cyclic GMP, and the vessel relaxes. Blood pressure drops. Tatemoto's group confirmed this by showing NOS inhibitors completely blocked the depressor response.

Inside cardiomyocytes, APJ fires through different branches. ERK1/2 phosphorylation and p70S6K signaling (via PKC) promote cell survival. Apelin-12 blocks mitochondrial cytochrome c release and shuts down caspase activation during ischemic stress. Cells that would die from oxygen deprivation get a survival signal instead.

The RAAS counter-regulation piece ties it together. APJ can physically hetero-dimerize with AT1 receptors. Apelin binding shifts the ACE/ACE2 balance toward ACE2, favoring cardioprotective Ang(1-7) over pathological Ang II. Apelin also suppresses TGF-beta1/Smad2/alpha-SMA fibrosis signaling (Lv et al., 2020), reducing collagen deposition and myofibroblast differentiation. Beta-arrestin-mediated APJ internalization begins within minutes of agonist binding, which is why receptor desensitization becomes relevant with repeated dosing.

Apelin-12 Benefits

  • Apelin-12 benefits center on cardiovascular protection and NO-dependent vasodilation. All evidence remains preclinical.
  • Dropped mean arterial pressure by 26 plus or minus 5 mmHg at 10 nmol/kg IV in rats, more than double the response from apelin-13 (Tatemoto et al.)[1].
  • Reduced infarct size and cardiomyocyte death in myocardial ischemia-reperfusion models. A 2026 meta-analysis pooled 26 preclinical studies confirming this cardioprotective signal (Khatami et al.)[2].
  • Blocked angiotensin II-induced atrial fibrosis through TGF-beta1/Smad2/alpha-SMA pathway suppression in animal models (Lv et al., 2020, PMC7711167).
  • Counter-regulated the RAAS axis at the receptor level; apelin-knockout mice showed markedly worsened cardiac dysfunction and fibrosis when challenged with Ang II (Sato et al.)[3].
  • Promoted angiogenesis and cardiomyocyte survival through ERK1/2 and Akt activation in preclinical cardiac stress models.

Apelin-12: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 10 key studies·Research only

Potent APJ receptor agonist with well-characterized vasodilatory and cardioprotective effects in preclinical models; no human dosing data exists for native apelin-12 specifically: all human trials use [Pyr1]apelin-13 or small-molecule APJ agonists

Dosing studied: 50–300 mcg/day SC (extrapolated from rat 10 nmol/kg IV; no human apelin-12 equivalents established)
Read the evidence (key study, limitations)
Key Study

Cardioprotective Effects of Apelin in Myocardial Ischemia/Reperfusion Injury: A Systematic Review and Meta-Analysis (Khatami et al., J Cardiovasc Pharmacol, Feb 2026, PMID 41150851): 26 preclinical studies; apelin-12 not isolable as a distinct subgroup. AMG 986 Phase 1b (Hellawell et al. 2022, PMID 35460392) tested a small-molecule APJ agonist in HFrEF patients: no clinically meaningful benefit observed.

Limitations

All human apelin research uses [Pyr1]apelin-13 isoform (e.g., Edinburgh CKD crossover trial, Nature Comm 2024, PMID 39402039): not apelin-12. Plasma half-life ~5 minutes makes SC bioavailability uncharacterized and likely inadequate for sustained APJ engagement. No in vivo PK data for SC apelin-12 in any species.

Community Experience
Weak
3.5/5
Based on ~0 reports

No community use: zero Reddit threads found across r/peptides, r/nootropics, r/longevity, r/PeptideResearch.

Community dosing: N/A: no community protocols exist
Read the reports (common issues 4)

No grey-market apelin-12 product exists. No self-administration protocols exist anywhere.

What users report (0)
    Common issues (4)
    • ~5-minute plasma half-life makes SC efficacy mechanistically uncertain: all animal pharmacology used IV bolus
    • Cost-prohibitive for self-administration: $42–110/mg, sold only as a lab reagent for research
    • Absent from grey-market peptide catalogs checked
    • No compounding pharmacy produces apelin-12
    Science-Only Evidence

    Apelin-12 has zero community use footprint. It exists exclusively in preclinical cardiovascular research. All human APJ agonist work uses [Pyr1]apelin-13 isoform or small molecules: the community has never adopted native apelin-12.

    Apelin-12 Dosage Guide

    SpeculativeVery limited human data: dose based on preclinical research
    LevelDose / InjectionFrequency
    Beginner50 mcg
    DailyTrack
    Moderate150 mcg
    DailyTrack
    Aggressive300 mcg
    DailyTrack
    Note:

    Reconstitution math for a 2 mg vial: add 2 mL bacteriostatic water to get 1 mg/mL (1000 mcg/mL). At that concentration, the beginner dose of 50 mcg is 5 units on a 100-unit insulin syringe. Moderate (150 mcg) is 15 units. Aggressive (300 mcg) is 30 units.

    With a 5 mg vial and 2 mL bacteriostatic water, you get 2.5 mg/mL (2500 mcg/mL). Beginner dose becomes 2 units. Moderate is 6 units. Aggressive is 12 units.

    Reconstituted apelin-12 lasts about 7 days at 2 to 8 degrees Celsius. Don't prep more than a week's supply at a time. Lyophilized powder stores well at minus 20 degrees with desiccant.

    The five-minute half-life is the elephant in the room. Every impressive rat data point used IV bolus dosing. SC absorption kinetics for apelin-12 have never been measured in any species. If you see no BP response after two weeks at moderate dosing, inadequate SC bioavailability is the most likely explanation.

    You need a blood pressure cuff before you need a syringe. Baseline BP is not optional.

    Cycling Protocol

    On Period
    4 weeks
    Off Period
    2 weeks

    No established human cycling protocols exist. The 4-on/2-off recommendation is precautionary. The extremely short half-life (~5 minutes) means systemic accumulation is unlikely, but receptor desensitization with repeated daily dosing is a theoretical concern. APJ receptor internalization occurs rapidly after agonist binding, and repeated stimulation may downregulate surface receptor expression. Discontinue if any adverse effects such as dizziness, lightheadedness, or symptomatic hypotension occur.

    Calculate your Apelin-12 dose
    Free dosage calculator with syringe visualization

    Or use the universal Peptide Calculator for any peptide.

    Apelin-12 Protocols by Goal

    advancedClinical Trial4 weeks on / 2 weeks off (precautionary; no evidence basis)
    Conservative dose: loading
    Wk 1–2
    50 mcg · Once daily · Subcutaneous
    Moderate research dose
    Wk 3–4
    150 mcg · Once daily (or split BID every 12 hours) · Subcutaneous

    Expected: Unknown in humans. In rats (IV): 26±5 mmHg MAP reduction at peak. SC exposure may be insufficient for measurable hemodynamic effects given uncharacterized SC bioavailability. No efficacy endpoints are validated for human SC use.

    Monitor: Baseline BP required before first dose. Check BP at 15 and 30 min post-injection each day in week 1. Discontinue if diastolic drops below 60 mmHg or symptomatic hypotension occurs.

    How to Use Apelin-12

    1. 1
      Step 1

      Gather supplies: lyophilized apelin-12 vial, bacteriostatic water, alcohol swabs, 29-gauge or 30-gauge insulin syringe (100-unit), blood pressure cuff.

    2. 2
      Take seated blood pressure

      Record the reading. If systolic is below 100 or diastolic below 65, skip the dose.

    3. 3
      Clean the vial stopper with an alcohol swab

      Draw 2 mL bacteriostatic water for a 2 mg vial (yields 1000 mcg/mL). Inject the water slowly along the vial wall. Don't shake. Gentle swirling only.

    4. 4
      Draw the correct dose

      Beginner: 50 mcg = 5 units. Moderate: 150 mcg = 15 units. Aggressive: 300 mcg = 30 units. All calculations based on 1000 mcg/mL concentration.

    5. 5
      Step 5

      Clean the injection site on the lower abdomen with an alcohol swab. Pinch a fold of skin and insert the needle at 45 degrees. Inject slowly. Rotate sites daily.

    6. 6
      Remain seated for 30 minutes post-injection during week one

      Take blood pressure at 15 minutes and 30 minutes.

    7. 7
      Step 7

      If diastolic drops below 60 mmHg or dizziness occurs, lie flat and elevate your legs until it passes.

    8. 8
      Timing: morning, fasted

      Avoid dosing within 2 hours of antihypertensive medications.

    9. 9
      Step 9

      If splitting to BID (morning and evening, 12 hours apart), total daily dose should not exceed the aggressive tier of 300 mcg. BID dosing is entirely unvalidated.

    10. 10
      Store reconstituted vial at 2 to 8 degrees Celsius

      Label with the reconstitution date. Use within 7 days.

    Alternative Routes

    Intravenous (IV) infusion

    1 to 300 nmol/min IV infusion used in human [Pyr1]apelin-13 trials (Japp et al. 2010, PMID 20385929: 30 to 300 nmol/min systemic; Edinburgh CKD trial 2024, PMID 39402039: 1 and 30 nmol/min). No equivalent IV protocol tested for native apelin-12 in humans. 10 nmol/kg IV bolus used in rat studies.

    All published mechanistic pharmacology used IV bolus or slow infusion to characterize peak hemodynamic effects. SC is speculative. IV is not appropriate for self-administration outside a clinical research setting.

    Mixing your own vial? Use the Apelin-12 reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

    Apelin-12 Stacking Protocols

    Works With

    Avoid

    Sacubitril (Entresto / sacubitril-valsartan)

    HIGHEST PRIORITY INTERACTION: Neprilysin is the only enzyme that fully inactivates apelin peptides: ACE2 cleavage produces a 12-aa metabolite ([Pyr1]apelin-13(1-12)) that retains substantial vasodilatory activity (pKi 8.04, comparable forearm blood flow in humans, PMC5329011). Sacubitril blocks this sole full-inactivation pathway, potentially causing dramatically prolonged and amplified hypotensive and hemodynamic effects.

    Do not combine
    Antihypertensive medications (ACE inhibitors, ARBs, beta-blockers, calcium channel blockers)

    Apelin-12 is a potent NO-dependent vasodilator. No pharmacokinetic interaction data exists. Additive hypotension risk with any antihypertensive class is a genuine safety concern: the combination could cause symptomatic or dangerous blood pressure reduction.

    Do not combine
    Vasopressin / desmopressin

    Apelin directly opposes vasopressin action at V2 receptors in renal collecting ducts. Combined use may produce unpredictable fluid balance, sodium levels, and blood pressure effects.

    Estimated Cost

    Compounded
    Not available from compounding pharmacies: no established human clinical use pathway; absent from all grey-market peptide catalogs

    Pricing updated 2026-04-09

    Apelin-12 Side Effects

    No human safety data exists for apelin-12. Every risk assessment below comes from animal pharmacology and from the AMG 986 small-molecule APJ agonist trial (Hellawell et al. 2022)[4]. AMG 986 is a different compound class entirely.

    The most serious expected effect is hypotension. That's the primary pharmacodynamic action, not a side effect in the traditional sense. Apelin-12 drops blood pressure through NO-mediated vasodilation. In normotensive rats, the magnitude was large: 26 mmHg MAP reduction at 10 nmol/kg IV. Anyone already taking antihypertensive medications, or with baseline low blood pressure, faces additive risk with zero interaction data to guide dose adjustments.

    Orthostatic hypotension is a specific concern. Standing up within 30 minutes of injection could trigger dizziness, lightheadedness, or syncope. The protocol calls for remaining seated for 30 minutes post-injection during the first week.

    Fluid balance disruption deserves attention. Apelin directly opposes vasopressin action at V2 receptors in renal collecting ducts. What that means for sodium levels, urine output, and total body water during repeated daily dosing has never been studied. A basic metabolic panel (sodium, potassium, creatinine) at baseline and at the end of each 4-week cycle is the minimum monitoring.

    Standard subcutaneous injection site reactions (redness, swelling, mild pain) are expected with any injectable peptide. No immunogenicity data exists for repeated exogenous apelin-12 administration in humans.

    The AMG 986 Phase 1b trial tested its small-molecule APJ agonist in healthy subjects and heart failure patients up to 650 mg/day. The safety profile was acceptable. No clinically significant dose-related findings emerged over 14 days. That provides some reassurance about APJ agonism as a target; it tells you nothing about the safety of a 12-amino-acid peptide with a five-minute half-life.

    APJ receptor desensitization matters pharmacologically. APJ is a class A GPCR that internalizes rapidly after agonist binding. Repeated daily stimulation may downregulate surface receptor expression, reducing response over time. If any initial hemodynamic effect (warmth, mild vasodilation) fades around days 7 through 14, desensitization is the likely explanation.

    Contraindications: hypotension or orthostatic hypotension, concurrent antihypertensive medications without physician oversight, pregnancy or breastfeeding (zero reproductive toxicology data), active hemorrhage, severe renal impairment, and known hypersensitivity to apelin peptides.

    The sacubitril interaction deserves its own callout. Neprilysin is the only enzyme that fully inactivates apelin peptides (PMC5329011). Sacubitril blocks neprilysin. Taking apelin-12 while on Entresto (sacubitril/valsartan) could dramatically prolong and amplify the hypotensive response. Avoid that combination entirely.

    Stop and consult a physician if blood pressure drops below 90/60 mmHg, if dizziness persists, or if presyncope occurs.

    Common Issues & Solutions

    BP drop >15 mmHg post-injection: reduce dose to 25 mcg: this confirms systemic exposure; further escalation should be paused until BP stabilizes

    No perceived effect after 2 weeks: likely reflects inadequate SC bioavailability: all animal pharmacology used IV bolus; the SC fraction reaching circulation is unknown and possibly negligible for a 5-min half-life peptide

    APJ receptor desensitization: if any initial hemodynamic response (mild warmth, slight vasodilation) diminishes over days 7–14, reduce frequency before increasing dose: class A GPCRs including APJ internalize rapidly after agonist binding

    Peptide degradation: reconstituted apelin-12 is stable only ~7 days at 2–8°C; if no response is observed, verify peptide preparation date and storage conditions before attributing failure to SC bioavailability

    BID dosing: if splitting doses (morning and evening) to compensate for short half-life, monitor for cumulative daily BP reduction; total daily dose should not exceed the aggressive tier (300 mcg/day) without increasing monitoring frequency

    Ask AI about this page

    Ask AI for a second opinion on Apelin-12 dosing and side effects

    Contraindications

    • Hypotension or orthostatic hypotension: apelin-12 is a potent vasodilator and could worsen low blood pressure
    • Concurrent use of multiple antihypertensive medications: additive hypotensive risk with no interaction data
    • Pregnancy or breastfeeding: no reproductive toxicology data exists for exogenous apelin-12
    • Active hemorrhage or conditions with compromised hemodynamic stability
    • Known hypersensitivity to apelin peptides or related compounds
    • Severe renal impairment: apelin interacts with vasopressin-mediated water balance in the kidney; effects on fluid handling in renal failure are unknown

    Drug Interactions

    • ACE inhibitors (enalapril, lisinopril): apelin-12 is degraded by ACE2; ACE inhibitors may shift ACE/ACE2 balance and alter apelin metabolism unpredictably
    • ARBs (losartan, valsartan): APJ hetero-dimerizes with AT1 receptors; blocking AT1 while stimulating APJ has unstudied combined effects
    • Beta-blockers: additive blood pressure lowering when combined with apelin-mediated vasodilation
    • Calcium channel blockers (amlodipine, diltiazem): additive hypotensive effects; no interaction data available
    • Neprilysin inhibitors (sacubitril): neprilysin degrades apelin; inhibition could prolong apelin-12 half-life and amplify effects
    • Vasopressin or desmopressin: apelin opposes vasopressin action at the V2 receptor in renal collecting ducts; concurrent use may produce unpredictable water balance effects
    • Other vasoactive peptides (BPC-157, SS-31, MOTS-c): no combination data available; theoretical additive cardiovascular effects

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    Seated blood pressure (manual or validated digital cuff)Baseline pre-dose; 15 min and 30 min post-injection for all of week 1; then before each injection thereafterSystolic >100 mmHg and diastolic >60 mmHg post-injection
    Orthostatic blood pressure (standing vs. seated)Baseline and weekly during use<20 mmHg systolic drop upon standing
    Basic metabolic panel (BMP): sodium, potassium, creatinineBaseline and at end of 4-week cycleSodium 136–145 mEq/L; creatinine within personal baseline range
    Seated blood pressure (manual or validated digital cuff)

    Primary pharmacodynamic effect is NO-mediated vasodilation causing BP reduction: this is the only measurable biomarker of actual drug effect accessible outside a clinical setting

    Orthostatic blood pressure (standing vs. seated)

    Vasodilation combined with postural change can trigger orthostatic hypotension and syncope; especially relevant in the 15–30 min window post-injection

    Basic metabolic panel (BMP): sodium, potassium, creatinine

    Apelin opposes vasopressin-mediated water reabsorption at V2 receptors in the renal collecting duct; sodium and fluid balance disruption is theoretically possible with sustained use; creatinine monitors renal function in context of fluid shifts

    Apelin-12 Before and After

    Minutes 0-30

    In animal models, intravenous apelin-12 produces an immediate blood pressure reduction peaking within minutes. The 26 mmHg mean arterial pressure drop in rats occurred rapidly after injection and was transient due to the ~5-minute half-life. Any perceived hemodynamic effect in humans would be expected in this acute window.

    Weeks 1-2

    No established human timeline exists. In repeated-dose animal studies, daily administration maintained cardioprotective signaling. Theoretical subcutaneous dosing would produce brief daily peaks of APJ activation. Measurable biomarker changes (e.g., NO metabolites, blood pressure trends) might be detectable with daily dosing in this timeframe.

    Weeks 2-4

    In animal I/R injury models, apelin treatment over 2-4 weeks reduced cardiac fibrosis markers and improved ejection fraction measurements. Anti-fibrotic effects via TGF-beta1/Smad2 pathway suppression were apparent in this timeframe in rodent studies.

    Weeks 4+

    Long-term data comes from apelin-knockout rescue experiments and chronic infusion studies in rodents. Sustained APJ activation over weeks to months improved cardiac remodeling outcomes. No long-term human data exists for native apelin-12 peptide. The AMG 986 small-molecule APJ agonist was tested for up to 14 days in humans without safety signals.

    What to Expect

    Minutes 0 to 30: The entire pharmacodynamic window lives here. IV apelin-12 at 10 nmol/kg produced a peak MAP reduction of 26 mmHg within minutes in rats. The effect fully resolved inside 30 minutes because of the five-minute half-life. Any hemodynamic response you might feel (warmth, mild flushing, lightheadedness from NO-mediated vasodilation) happens and ends in this window.

    Weeks 1 to 2: Daily dosing in animal models maintained cardioprotective signaling (PI3K/Akt/eNOS and ERK1/2) with repeated injections. For SC dosing in humans, the honest answer is uncertain. SC bioavailability has never been measured. You might detect trends in resting blood pressure if the peptide reaches systemic circulation. Keep logging BP at 15 and 30 minutes post-injection.

    Weeks 2 to 4: Rodent ischemia-reperfusion and cardiomyopathy models showed reduced fibrosis markers and improved ejection fraction over this timeframe. Most of that data used apelin-13, not apelin-12. Anti-fibrotic effects through TGF-beta1/Smad2 suppression were apparent in rodent tissue. Whether SC apelin-12 achieves enough human systemic exposure to replicate this is genuinely uncertain. Watch for signs of APJ desensitization around days 7 through 14.

    Weeks 4 and beyond: Long-term data comes from knockout rescue experiments and chronic infusion studies in rodents. Sustained APJ activation over weeks to months improved cardiac remodeling. AMG 986 (the small-molecule APJ agonist) was tested safely for 14 days in HFrEF patients but showed no clinically meaningful pharmacodynamic benefit [4]. No long-term human data exists for native apelin-12. The 4-on/2-off cycling schedule is precautionary, not evidence-based.

    Detailed Timeline: Science vs Community

    Minutes 0–30
    Science

    IV apelin-12 (10 nmol/kg) produces peak MAP reduction of 26±5 mmHg in normotensive rats within minutes; effect fully resolves within ~30 minutes due to 5-min t½. The entire pharmacodynamic window is contained in this period for each injection.

    Community

    No reports exist: no community use

    Weeks 1–2
    Science

    Daily dosing in animal models maintained cardioprotective signaling cascades (PI3K/Akt/eNOS, ERK1/2) with repeated dosing. SC bioavailability in humans is unknown: effects may not accumulate meaningfully if the peptide degrades before significant absorption.

    Community

    No reports exist

    Weeks 2–4
    Science

    Rodent I/R and cardiomyopathy models showed reduced cardiac fibrosis markers and improved ejection fraction over 2–4 weeks of apelin treatment. Note: these studies predominantly used apelin-13 isoforms, not apelin-12 specifically.

    Community

    No reports exist

    Weeks 4+
    Science

    Apelin-knockout rescue experiments and chronic infusion models in rodents showed improved cardiac remodeling with sustained multi-week exposure. AMG 986 (small-molecule APJ agonist) was tested safely for 14 days in HFrEF patients but produced no clinically meaningful pharmacodynamic benefit. No long-term human data for native apelin-12.

    Community

    No reports exist

    Pharmacokinetics

    Half-Life
    5min
    Bioavailability
    SC: not formally characterized for apelin-12. IV: 100% by definition. Intranasal and oral bioavailability not established. Native peptide undergoes rapid proteolytic degradation in plasma.
    Tmax
    IV: immediate peak effect within 1-2 minutes in rat studies. SC: estimated Tmax < 15 minutes based on peptide absorption kinetics, though no formal SC PK study has been published for apelin-12.
    Data Confidence
    low

    Source: Native apelin peptides have an extremely short plasma half-life of approximately 5 minutes in circulation. ACE2 is the principal endopeptidase responsible for apelin inactivation, cleaving the C-terminal Pro-Phe bond. Neprilysin (NEP 24.11) also hydrolyzes apelin peptide bonds. Tatemoto et al. (2001) demonstrated the transient hemodynamic response consistent with rapid clearance. Modified apelin analogues with lipidation can extend half-life to ~29 hours in rat plasma.

    Pharmacokinetics: Active Dose Over Time

    t½ = ~5 minutes (native peptide, rapid ACE2/neprilysin degradation in plasma)

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    12
    Sequence
    RPRLSHKGPMPF
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
    Identifiers
    CAS: 229961-08-4

    Who Should Consider Apelin-12

    • Researchers studying the apelin/APJ signaling axis in cardiovascular disease models
    • Scientists investigating endogenous counter-regulatory peptides to the RAAS system
    • Individuals exploring experimental cardioprotective peptides under physician supervision
    • Researchers studying NO-dependent vasodilation pathways and blood pressure regulation
    • Those investigating anti-fibrotic strategies for cardiac remodeling prevention

    Related Peptides

    What Changed for Apelin-12

    No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

    Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations

    References

    1. [1]The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism (Tatemoto et al., 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Cardioprotective effects of apelin in myocardial ischemia/reperfusion injury: a systematic review and meta-analysis (2025) (opens in a new tab)PubMed (opens in a new tab)Review
    3. [3]Loss of apelin augments angiotensin II-induced cardiac dysfunction and pathological remodeling (Sato et al., 2019) (opens in a new tab)PubMed (opens in a new tab)PubMed
    4. [4]A first-in-human study of AMG 986, a novel apelin receptor agonist, in healthy subjects and heart failure patients (Hellawell et al., 2022) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial

    Related Tools

    Storage & Stability

    Before Reconstitution
    Stable at room temperature for up to 2 weeks; store at -20°C for long-term preservation
    After Reconstitution
    Refrigerate at 2-8°C, use within 7 days due to short peptide stability
    Temperature
    2-8°C (36-46°F) short-term; -20°C (-4°F) long-term

    Frequently Asked Questions

    No. Apelin-12 (RPRLSHKGPMPF) is the shortest synthetic form retaining APJ agonism. [Pyr1]apelin-13 is the predominant endogenous cardiovascular isoform. ACE2 cleaves apelin-13 to produce a 12-amino-acid metabolite structurally similar to synthetic apelin-12, but with a different N-terminus. They are different molecules.

    Not completely. ACE2 cleaves the C-terminal phenylalanine from apelin-13/17, producing a 12-aa metabolite that retains substantial vasodilatory activity; comparable binding affinity and forearm blood flow increases in healthy humans (PMC5329011). Only neprilysin generates fully inactive fragments, which makes sacubitril the most pharmacologically significant drug interaction.

    The ~5-minute plasma half-life is the primary barrier. Amgen's AMG 986 (oral small-molecule APJ agonist) attempted to solve this. The Phase 1b trial (Hellawell et al. 2022, PMID 35460392) showed acceptable safety up to 650 mg/day but no clinically meaningful benefit in HFrEF patients.

    For acute blood pressure reduction in normotensive rats, yes; 26±5 mmHg MAP reduction vs. 11±4 for apelin-13 at 10 nmol/kg IV. However, apelin-17 has the highest APJ binding affinity (pKi ~9.0) and is most potent in cAMP assays. Potency ranking is isoform- and assay-dependent.

    No published combination data exists. The 5-minute half-life makes achieving meaningful systemic exposure with SC injection uncertain, and the additive hypotensive risk with any vasoactive combination is a genuine safety concern.